Patent ID: 8563710
Filing Date: 2013-10-22
Classification: A61K,A61P,C12N,Y10T

Abstract:
1. A modified oligonucleotide comprising a first nucleic acid fragment and a second nucleic acid fragment, wherein each of said first nucleic acid fragment and said second nucleic acid fragment is 18 to 30 nucleotides in length; said first nucleic acid fragment and said second nucleic acid fragment can form double-stranded region; said first nucleic acid fragment contains at least one contiguous CA or UG sequence, said second nucleic acid fragment contains at least one contiguous CA or UG sequence complementary to the CA or UG sequence in said first nucleic acid fragment, the CA or UG sequence(s) of said first nucleic acid fragment and the CA or UG sequence(s) of said second nucleic acid fragment pair to form CA/UG and/or UG/CA site(s); wherein at least one of the nucleotides in at least one of the CA/UG and/or UG/CA site(s) is a modified nucleotide; wherein all other nucleotides are unmodified nucleotides; and said modified nucleotide(s) providing improved stability of said modified oligonucleotide in mammalian serum compared to stability of an unmodified oligonucleotide.